Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 1 80 21 versus ORTHO TRI CYCLEN 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 1 80 21 versus ORTHO TRI CYCLEN 21.
ORTHO-NOVUM 1/80 21 vs ORTHO TRI-CYCLEN 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases viscosity of cervical mucus, impeding sperm penetration. Induces endometrial thinning, reducing implantation likelihood.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
One tablet orally once daily for 21 consecutive days, followed by 7 days off therapy.
One tablet daily for 21 days, followed by 7 days of placebo, then repeat. Each tablet contains 0.180 mg norgestimate and 0.035 mg ethinyl estradiol (days 1–7), 0.215 mg/0.035 mg (days 8–14), and 0.250 mg/0.035 mg (days 15–21). Oral route.
None Documented
None Documented
Norethindrone terminal half-life: 8-11 hours; Mestranol (ethinyl estradiol pro-drug) terminal half-life: 10-15 hours (metabolite ethinyl estradiol). Clinical context: Steady-state reached in 5-7 days; once-daily dosing maintains therapeutic levels.
Norgestimate: ~24 hours (terminal); ethinyl estradiol: ~17 hours (terminal). Steady-state achieved within 5-7 days; clinical significance: missed doses may increase contraceptive failure risk.
Renal: ~60% (metabolites, primarily glucuronide and sulfate conjugates), Fecal: ~40% (biliary excretion of metabolites). Unchanged drug negligible.
Renal: ~70% (metabolites, primarily glucuronide and sulfate conjugates of norgestimate and ethinyl estradiol); Fecal: ~30% (biliary elimination of unchanged drug and metabolites).
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive